Authors, journal, year
Country
Study design
Therapies and number of participants per study group
Measures
Number of measurements
AS compared to curative treatment
1. Jeldres et al., cancer, 2015 [15]
USA
Longitudinal
AS n = 77, RP n = 228
EPIC
Baseline (before or after biopsy), 3, 6, 9, 12, 18, 24, and 36 months
2. Van den Bergh et al., Scand J Urol, 2014 [16]
The Netherlands
Observational
AS robot-assisted RP n = 29, Robot-assisted RP n = 363
EORTC-QLQ-PR25, IIEF-15, ICIQ-SF
One preoperative and one postoperative
3. Watson et al., BJUI, 2015 [17]
UK
Cross-sectional
Surgery n = 115, RT n = 36, RT with adjuvant HT n = 81, primary HT n = 36, AS n = 43
EPIC-26
One between 9 and 24 months after diagnosis
4. De Cerqueira et al., Eur J cancer care, 2015 [18]
Brazil
Cross-sectional
Focal cryotherapy n = 10, brachytherapy n = 9, AS n = 11
IPSS
One between ≥12 or ≤24 months of diagnosis or treatment follow-up
5. Van den Bergh et al., BJUI, 2012 [19]
The Netherlands
Longitudinal
AS n = 129, RP n = 67, RT n = 70
10 items on sexual function
AS, 6 and 18 months after diagnosis; RP&RT, 6 and 12 months after start of treatment
6. Pham et al., J Urology, 2016 [20]
USA
Longitudinal
Non-cancer n = 420, AS n = 89
EPIC
Baseline (before or after biopsy), 12, 24, and 36 months
Single AS studies
7. Hilton et al., J Urology, 2012 [22]
USA
Longitudinal
AS one biopsy n = 427, AS two biopsies n = 220, AS three biopsies n = 70
SHIM
Every 6 months
8 Pearce et al., sexual medicine, 2015 [23]
USA
Longitudinal
AS n = 195
EPIC, AUA-SI
Baseline, 6, 12, 18, and 24 months
9. Parker et al., BJUI, 2016 [24]
USA
Longitudinal
AS n = 180
EPIC
Time of enrollment and then every 6 months for up to 30 months
10. Fujita et al., J Urology, 2009 [12]
USA
Observational
AS n = 152
SHIM, IPSS
Baseline and one measurement in March 2008
Table 15.2
Details of studies into anxiety and distress
Authors, journal, year | Country | Study design | Therapies and number of patients per study group | Measures | Number and timing of measurements |
|---|---|---|---|---|---|
AS compared to curative treatment | |||||
The Netherlands | Observational | AS robot-assisted RP n = 29, robot-assisted RP n = 363 | EORTC-QLQ-C30 | One preoperative and one postoperative | |
Brazil | Cross-sectional | Focal cryotherapy n = 10, brachytherapy n = 9, AS n = 11 | BAI, BDI, BHS, SF-36 MH | One between ≥12 or ≤24 months of diagnosis or treatment follow-up | |
Van den Bergh et al., BJUI, 2012 [19] | The Netherlands | Longitudinal | AS n = 129, RP n = 67, RT n = 70 | SF-12, (MCS), CES-D, STAI-6 | AS: 6 and 18 months after diagnosis; RP&RT: 6 and 12 months after start of treatment |
USA | Longitudinal | Non-cancer n = 420, AS n = 89 | SF-36 | Baseline (before or after biopsy), 12, 24, and 36 months | |
Single AS studies | |||||
USA | Longitudinal | AS n = 195 | AUA-SI, MAX-PC | Baseline (before or after biopsy), 12, 24, and 36 months | |
USA | Longitudinal | AS n = 180 | MUIS-STAI, SF-12, fear of disease progression/recurrence with subscale MAX-PC | Time of enrollment and then every 6 months for up to 30 months | |
The Netherlands | Longitudinal | AS n = 129 | MAX-PC, STAI-6, CES-D | Baseline (<6 months after diagnosis), and after 9 an 18 months | |
Watts et al., BMJ Open, 2015 [32] | UK | Cross-sectional
 Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
Get Clinical Tree app for offline access
| |||